The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has recently established the COVID-19 Prevention Network (CoVPN). Its goal is to register millions of volunteers for large-scale clinical testing of vaccines and monoclonal antibodies intended to protect people from COVID-19.
As part of this initiative, Oracle developed a Cloud System called the CoVPN Volunteer Screening Registry to identify and screen volunteers who want to participate in COVID-19 clinical trials. Even though the system has been live for less than a week, more than 100,000 people have already registered.
This program is expected to support hundreds of clinical trial sites across the United States and internationally by the end of the year. The trials are inclusive of absolutely everyone from all communities, with a focus on those who are at higher risk for COVID-19. We encourage you to visit the CoVPN website, learn more about the vaccine trial program, and volunteer if you are able at http://covpn.oracle.com/survey
The CoVPN Volunteer Screening Registry is the latest in a series of COVID-19 cloud application systems built by Oracle to support the U.S. Department of Health and Human Services (HHS), healthcare providers and medical researchers. Taken together, these systems are designed to enable health professionals to collect and analyze the data necessary to better understand and combat COVID-19.
In April, Oracle developed a Therapeutic Learning System (TLS) that allows physicians and patients to record responses to promising COVID-19 drug therapies. In partnership with health systems such as Wake Forest Baptist Health and Javara Research, the initiative was extended to include patient monitoring. Participating patients can easily log their symptoms on smartphones giving healthcare professionals immediate access to early warning signs. Over 1.5 million patient updates have already been recorded in TLS.
With this announcement, Oracle is expanding its cooperation with HHS to support the large-scale clinical trials required in the race for a vaccine.
To learn more about how Oracle is helping countless industries navigate COVID-19, visit: https://www.oracle.com/corporate/covid-19.html
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.